Barton, D.L., Thanarajasingam, G., Sloan, J.A., Diekmann, B., Fuloria, J., Kottschade, L.A., . . . Loprinzi, C.L. (2014). Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer, 120, 3575–3583.
To compare gabapentin to a placebo on three factors: efficacy in decreasing CINV, tolerability to the medication, and impact on quality of life.
This phase 3 study was a placebo-controlled trial that was randomized and double-blinded.
This study did not support the effectiveness of gabapentin as prophylaxis for delayed chemotherapy-induced nausea and vomiting when used in conjunction with dexamethasone and a 5HT3 receptor antagonist.
Based on this study, gabapentin is not recommended as prophylaxis for delayed chemotherapy-induced nausea and vomiting.